Additional support for its development as a nanomedicine for CXCR4+ EC comes from our previous work reporting a similar biodistribution of T22-GFP-H6 in other solid tumors or hematological cancers [38,39,40,48]. The gene discussed is CXCR4; the disease is hematopoietic and lymphoid cell neoplasm.